|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C16orf87 |
Gene summary for C16ORF87 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C16orf87 | Gene ID | 388272 |
| Gene name | chromosome 16 open reading frame 87 | |
| Gene Alias | C16orf87 | |
| Cytomap | 16q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q6PH81 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 388272 | C16orf87 | LZE4T | Human | Esophagus | ESCC | 1.73e-11 | 3.78e-01 | 0.0811 |
| 388272 | C16orf87 | LZE7T | Human | Esophagus | ESCC | 2.23e-06 | 4.79e-01 | 0.0667 |
| 388272 | C16orf87 | LZE8T | Human | Esophagus | ESCC | 1.46e-02 | 9.63e-02 | 0.067 |
| 388272 | C16orf87 | LZE20T | Human | Esophagus | ESCC | 1.18e-02 | 1.16e-01 | 0.0662 |
| 388272 | C16orf87 | LZE24T | Human | Esophagus | ESCC | 5.98e-08 | 4.58e-01 | 0.0596 |
| 388272 | C16orf87 | LZE21T | Human | Esophagus | ESCC | 1.25e-05 | 2.29e-01 | 0.0655 |
| 388272 | C16orf87 | P1T-E | Human | Esophagus | ESCC | 2.28e-06 | 2.77e-01 | 0.0875 |
| 388272 | C16orf87 | P2T-E | Human | Esophagus | ESCC | 2.08e-17 | 3.40e-01 | 0.1177 |
| 388272 | C16orf87 | P4T-E | Human | Esophagus | ESCC | 9.96e-24 | 6.30e-01 | 0.1323 |
| 388272 | C16orf87 | P5T-E | Human | Esophagus | ESCC | 3.92e-19 | 3.57e-01 | 0.1327 |
| 388272 | C16orf87 | P8T-E | Human | Esophagus | ESCC | 7.26e-27 | 5.26e-01 | 0.0889 |
| 388272 | C16orf87 | P9T-E | Human | Esophagus | ESCC | 6.50e-09 | 2.19e-01 | 0.1131 |
| 388272 | C16orf87 | P10T-E | Human | Esophagus | ESCC | 5.34e-27 | 3.49e-01 | 0.116 |
| 388272 | C16orf87 | P11T-E | Human | Esophagus | ESCC | 2.68e-21 | 7.27e-01 | 0.1426 |
| 388272 | C16orf87 | P12T-E | Human | Esophagus | ESCC | 5.70e-30 | 4.75e-01 | 0.1122 |
| 388272 | C16orf87 | P15T-E | Human | Esophagus | ESCC | 6.54e-26 | 4.60e-01 | 0.1149 |
| 388272 | C16orf87 | P16T-E | Human | Esophagus | ESCC | 4.92e-23 | 4.58e-01 | 0.1153 |
| 388272 | C16orf87 | P19T-E | Human | Esophagus | ESCC | 2.76e-04 | 4.75e-01 | 0.1662 |
| 388272 | C16orf87 | P20T-E | Human | Esophagus | ESCC | 2.48e-24 | 6.00e-01 | 0.1124 |
| 388272 | C16orf87 | P21T-E | Human | Esophagus | ESCC | 2.20e-25 | 3.77e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C16orf87 | SNV | Missense_Mutation | c.80N>T | p.Cys27Phe | p.C27F | Q6PH81 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| C16orf87 | SNV | Missense_Mutation | novel | c.91C>A | p.Pro31Thr | p.P31T | Q6PH81 | protein_coding | tolerated(0.07) | probably_damaging(0.995) | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| C16orf87 | SNV | Missense_Mutation | c.34N>A | p.Ala12Thr | p.A12T | Q6PH81 | protein_coding | tolerated(0.2) | possibly_damaging(0.811) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| C16orf87 | SNV | Missense_Mutation | novel | c.452N>T | p.Arg151Ile | p.R151I | Q6PH81 | protein_coding | deleterious(0) | possibly_damaging(0.558) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| C16orf87 | SNV | Missense_Mutation | novel | c.246N>C | p.Glu82Asp | p.E82D | Q6PH81 | protein_coding | tolerated(0.1) | probably_damaging(0.935) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| C16orf87 | SNV | Missense_Mutation | novel | c.339N>C | p.Glu113Asp | p.E113D | Q6PH81 | protein_coding | tolerated(0.18) | benign(0) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| C16orf87 | SNV | Missense_Mutation | novel | c.220N>C | p.Asn74His | p.N74H | Q6PH81 | protein_coding | tolerated(0.07) | benign(0) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C16orf87 | SNV | Missense_Mutation | novel | c.415N>A | p.Ala139Thr | p.A139T | Q6PH81 | protein_coding | tolerated(0.14) | probably_damaging(0.978) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| C16orf87 | SNV | Missense_Mutation | c.348G>T | p.Glu116Asp | p.E116D | Q6PH81 | protein_coding | tolerated(0.11) | benign(0.052) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C16orf87 | SNV | Missense_Mutation | novel | c.452N>T | p.Arg151Ile | p.R151I | Q6PH81 | protein_coding | deleterious(0) | possibly_damaging(0.558) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |